On June 3, 2024, Ikonisys S.A. closed the transaction. The company announced it has issued 100,000 new ordinary shares with a par value of ?0.50 each, issue price of ?1.5 per share for gross proceeds ? 150,000 in its second tranche.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 EUR | 0.00% |
|
+0.71% | -8.97% |
06-13 | Ulisse Biomed and Ikonisys together to innovate oncology diagnostics | AN |
06-12 | Ikonisys, Ulisse Biomed to Collaborate on New Cancer Diagnostic Technologies | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.97% | 16.05M | |
-11.78% | 11.24B | |
-13.76% | 7.29B | |
+29.50% | 5.57B | |
-0.19% | 5.31B | |
-19.19% | 3.68B | |
+7.62% | 2.58B | |
-65.24% | 2.33B | |
-10.48% | 2.23B | |
+27.80% | 2.21B |
- Stock Market
- Equities
- ALIKO Stock
- News Ikonisys S.A.
- Ikonisys S.A. announced that it has received ?1.150001 million in funding